Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia | NEJM
BCR-ABL1 and the Philadelphia chromosome - Part 3: The BCR-ABL fusion protein - YouTube
Mechanism of Action of BCR-ABL and of Its Inhibition by Imatinib. Panel... | Download Scientific Diagram
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface* - Journal of Biological Chemistry
Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics: Cancer Cell
Figure 1 from STI571: targeting BCR-ABL as therapy for CML. | Semantic Scholar
Hematology Reports | Free Full-Text | Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
Structure and Dynamic Regulation of Abl Kinases* - ScienceDirect
Frontiers | The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
Regulation of the c-Abl and Bcr–Abl tyrosine kinases | Nature Reviews Molecular Cell Biology
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. - Australian Medical Student Journal